6-Methyl-2-(3-methyl-butyryl)-1-oxa-5-aza-spiro[2.5]oct-6-ene-4,8-dione

ID: ALA62236

Chembl Id: CHEMBL62236

Cas Number: 38473-18-6

PubChem CID: 10444160

Max Phase: Preclinical

Molecular Formula: C12H15NO4

Molecular Weight: 237.25

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC1=CC(=O)[C@@]2(O[C@H]2C(=O)CC(C)C)C(=O)N1

Standard InChI:  InChI=1S/C12H15NO4/c1-6(2)4-8(14)10-12(17-10)9(15)5-7(3)13-11(12)16/h5-6,10H,4H2,1-3H3,(H,13,16)/t10-,12-/m0/s1

Standard InChI Key:  DWCXXICTUDDKTB-JQWIXIFHSA-N

Alternative Forms

1. Parent:

   

   ALA62236

   Flavipucine

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 237.25

Molecular Weight (Monoisotopic): 237.1001

AlogP: 0.34

#Rotatable Bonds: 3

Polar Surface Area: 75.77

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.55

CX Basic pKa: ┄

CX LogP: 0.93

CX LogD: 0.93

Aromatic Rings: ┄

Heavy Atoms: 17

QED Weighted: 0.57

Np Likeness Score: 1.00

References

1. Girotra NN, Patchett AA, Zimmerman SB, Achimov DL, Wendler NL..  (1980)  Synthesis and biological activity of flavipucine analogues.,  23  (2): [PMID:7359536] [10.1021/jm00176a019]

2. Kusakabe Y, Mizutani S, Kamo S, Yoshimoto T, Tomoshige S, Kawasaki T, Takasawa R, Tsubaki K, Kuramochi K..  (2019)  Synthesis, antibacterial and cytotoxic evaluation of flavipucine and its derivatives.,  29  (11): [PMID:30935798] [10.1016/j.bmcl.2019.03.034]

Source

Source(1):

• Scientific Literature